Formed in 2009, Biosensia is a science focused, venture backed business established specifically to develop and exploit this novel and proprietary technology, RapiPlex. Biosensia is interested in exploring product commercialisation under license agreement.
The company has core skills in immunology, biochemistry, microbiology, physics, microfluidics, design engineering, software development and quality/regulatory affairs. Our aim is to make RapiPlex a method of choice for testing multiple analytes in a matter of minutes.